Insights

Growing Market Presence Oncospace has established strategic partnerships with leading institutions such as the University of Washington and TECNOLOGIE AVANZATE T.A. Srl, as well as expanding into the UK and Ireland via Xiel Ltd. These collaborations indicate an active effort to increase market penetration in key regions, presenting opportunities to offer tailored solutions that support their expansion efforts.

Recent Acquisition & Expansion The acquisition by Sun Nuclear, a Mirion Medical brand, enhances Oncospace’s credibility and resource base, positioning it as a more competitive player in the radiation oncology technology landscape. This move could accelerate development and deployment of innovative solutions, opening up sales opportunities for advanced, integrated radiation therapy planning tools.

Innovative Technology Usage Built on a cloud-first platform with AI-powered capabilities, Oncospace offers predictive treatment planning that automates complex workflows. Its focus on data-driven solutions aligns well with the needs of large institutional clients seeking to improve accuracy and efficiency in radiation therapy, creating potential opportunities for upselling or expanding enterprise deployments.

Market Trends & Compliance With a focus on modernization and sharing expertise through collaborative relationships, Oncospace is positioned well to meet ongoing industry trends toward digital transformation and data interoperability in healthcare. This presents sales prospects for complementary solutions such as data migration, integration services, and compliance tools to support their collaborative initiatives.

Financial & Growth Potential Despite a current revenue range of zero to one million dollars, the company’s strategic partnerships and recent acquisition suggest significant growth potential. As Oncospace expands its customer base and leverages its innovative SaaS offerings, there are substantial opportunities to introduce scalable solutions tailored for small to mid-sized radiation oncology practices seeking modern planning tools.

Oncospace Tech Stack

Oncospace uses 8 technology products and services including RSS, WordPress, Open Graph, and more. Explore Oncospace's tech stack below.

  • RSS
    Content Management System
  • WordPress
    Content Management System
  • Open Graph
    Content Management System
  • oEmbed
    Dev Tools
  • JSON-LD
    Javascript Frameworks
  • Elementor
    Page Builders
  • HSTS
    Security
  • Nginx
    Web Servers

Media & News

Oncospace's Email Address Formats

Oncospace uses at least 1 format(s):
Oncospace Email FormatsExamplePercentage
First.Last@oncospace.comJohn.Doe@oncospace.com
95%
Last.F@oncospace.comDoe.J@oncospace.com
5%

Frequently Asked Questions

What is Oncospace's official website and social media links?

Minus sign iconPlus sign icon
Oncospace's official website is oncospace.com and has social profiles on LinkedInCrunchbase.

What is Oncospace's NAICS code?

Minus sign iconPlus sign icon
Oncospace's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Oncospace have currently?

Minus sign iconPlus sign icon
As of July 2026, Oncospace has approximately 4 employees across 1 continents, including North America. Key team members include Co-Founder, Chief Scientist, Cob: T. M.Board Member: J. S.Data Scientist: S. M.. Explore Oncospace's employee directory with LeadIQ.

What industry does Oncospace belong to?

Minus sign iconPlus sign icon
Oncospace operates in the Medical Equipment Manufacturing industry.

What technology does Oncospace use?

Minus sign iconPlus sign icon
Oncospace's tech stack includes RSSWordPressOpen GraphoEmbedJSON-LDElementorHSTSNginx.

What is Oncospace's email format?

Minus sign iconPlus sign icon
Oncospace's email format typically follows the pattern of First.Last@oncospace.com. Find more Oncospace email formats with LeadIQ.

How much funding has Oncospace raised to date?

Minus sign iconPlus sign icon
As of July 2026, Oncospace has raised $1.3M in funding. The last funding round occurred on Feb 18, 2021 for $1M.

When was Oncospace founded?

Minus sign iconPlus sign icon
Oncospace was founded in 2019.
Oncospace logo

Oncospace

Medical Equipment ManufacturingMaryland, United States2-10 Employees

Oncospace develops software aimed at improving radiation therapy planning and knowledge sharing within the oncology community. Based in Baltimore, Maryland, the company operates with a small team and offers a cloud-based, software-as-a-service platform that leverages artificial intelligence and data insights to help clinicians predict feasible treatment plans for prostate and head-and-neck cancers, automate parts of the planning process, and promote consistent adherence to best practices. The platform is intended for radiation oncology practices and patients, supporting more consistent, data-driven planning and facilitating sharing of clinical expertise. In April 2025, Oncospace was acquired by Sun Nuclear, a Mirion Medical brand, which seeks to extend the reach and impact of its solutions in the radiation therapy field. This integration positions Oncospace within a broader medical technology portfolio and aims to enhance the quality and accessibility of treatment.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2019
Employees
2-10

Section iconFunding & Financials

  • $1.3M

    Oncospace has raised a total of $1.3M of funding over 3 rounds. Their latest funding round was raised on Feb 18, 2021 in the amount of $1Mas a grant.

  • $1M

    Oncospace's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1.3M

    Oncospace has raised a total of $1.3M of funding over 3 rounds. Their latest funding round was raised on Feb 18, 2021 in the amount of $1Mas a grant.

  • $1M

    Oncospace's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.